Speech-Language Pathologists in Evans City, PA Accepting Medicare

1 Speech-Language Pathologists found. Showing 1 - 1

Mary Ann Mccoppin, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 336 Old Route 68, Evans City, PA 16033 Phone: 724-553-0597

News Archive

CNIO researchers identify over 40 genes that predict aggressiveness of melanoma

Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. The discovery, published in Cancer Cell, will help to identify unique aspects of melanoma that could contribute to determine the risk of developing metastasis in patients with this disease.

Media examines food summit reaction, malnutrition in Liberia, Yemen

VOA News reports on reactions from last week's U.N. World Summit on Food Security in Rome: "The delegates in Rome promised to continue efforts to reduce by half the number of hungry people by two thousand fifteen. But critics pointed out that world leaders made a similar promise more than ten years ago. Several countries promised to increase aid for agriculture, to help developing nations become more independent. Still, critics deplored a lack of greater action" (Simms, 11/22).

USPSTF recommends against ovarian cancer screening in women without symptoms

The U.S. Preventive Services Task Force (USPSTF) recommends against screening for ovarian cancer in women without symptoms and who are not known to be at high risk (such as those who have certain hereditary cancer syndromes that increase the risk for ovarian cancer).

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

Read more Medical News

› Verified 3 days ago